

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
T cell lymphoma	c-Myc	<p>Studies in mice suggest that increasing CD4⁺ T cell function may increase the efficacy of oncogene-targeted cancer therapeutics. In an immunocompromised mouse model of T cell acute lymphoblastic lymphoma (ALL) with an inactivated <i>c-Myc</i> oncogene, adoptive transfer of CD4⁺ T cells prolonged tumor-free survival compared with no adoptive transfer. Next steps include elucidating the mechanisms by which CD4⁺ T cells increase tumor regression after oncogene inactivation.</p> <p>SciBX 3(43); doi:10.1038/scibx.2010.1287 Published online Nov. 4, 2010</p>	<p>Patent pending; available for licensing from the Stanford University Office of Technology Licensing</p>	<p>Rakhra, K. <i>et al. Cancer Cell</i>; published online Oct. 28, 2010; doi:10.1016/j.ccr.2010.10.002 Contact: Dean W. Felsher, Stanford University School of Medicine, Palo Alto, Calif. e-mail: dfelsher@stanford.edu</p>